Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Germline BRCA1/2 Mutations and”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT05485766
What this trial is testing

Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast NeoplasmsTriple Negative Breast CancerBreast Neoplasms+5 more
Okayama University 23
Not applicableUnknownNCT05763472
What this trial is testing

Breast Cancer After Ovarian Cancer During and/or After Therapy: Genomic Evaluation

Who this might be right for
BRCA-Associated Breast Carcinoma
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 10
Testing effectiveness (Phase 2)Active Not RecruitingNCT03344965
What this trial is testing

Olaparib In Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerInvasive Breast CancerSomatic Mutation Breast Cancer (BRCA1)+7 more
Beth Israel Deaconess Medical Center 114
Not applicableStudy completedNCT05141708
What this trial is testing

Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative mBC With gBRCA1/2m

Who this might be right for
Metastatic Breast CancerBreast Neoplasms
Pfizer 33
Testing effectiveness (Phase 2)UnknownNCT04556292
What this trial is testing

A Phase II Study to Assess the Efficacy and Safety of SC10914 in the Metastatic Breast Cancer Patients

Who this might be right for
Breast Cancer MetastaticBRCA 1 Gene MutationBRCA 2 Gene Mutation
Jiangxi Qingfeng Pharmaceutical Co. Ltd. 78
Not applicableStudy completedNCT04987931
What this trial is testing

Real-World Outcomes of US Talazoparib-Treated Patients With Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Pfizer 84
Testing effectiveness (Phase 2)Active Not RecruitingNCT05033756
What this trial is testing

Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO

Who this might be right for
Malignant Neoplasm of BreastBreast Cancer
Institut fuer Frauengesundheit 11
Testing effectiveness (Phase 2)Active Not RecruitingNCT03330847
What this trial is testing

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

Who this might be right for
Metastatic Triple Negative Breast Cancer
AstraZeneca 273
Testing effectiveness (Phase 2)Ended earlyNCT03140670
What this trial is testing

Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy

Who this might be right for
Pancreatic Cancer
Abramson Cancer Center at Penn Medicine 46
Large-scale testing (Phase 3)Study completedNCT02184195
What this trial is testing

Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy

Who this might be right for
Germline BRCA1/2 Mutations andMetastatic Adenocarcinoma of the Pancreas
AstraZeneca 154
Large-scale testing (Phase 3)Looking for participantsNCT06533384
What this trial is testing

PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC

Who this might be right for
Triple-negative Breast Cancer
Guangdong Provincial People's Hospital 310
Post-approval studies (Phase 4)Study completedNCT04330040
What this trial is testing

Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer

Who this might be right for
Ovarian CancerBreast Cancer
AstraZeneca 202
Large-scale testing (Phase 3)Study completedNCT02282020
What this trial is testing

Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments

Who this might be right for
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
AstraZeneca 266
Testing effectiveness (Phase 2)Study completedNCT04089189
What this trial is testing

Study of IMP4297 in Patients With BRCA1/2 Mutation Ovarian Cancer

Who this might be right for
Ovarian Cancer
Impact Therapeutics, Inc. 93
Large-scale testing (Phase 3)Study completedNCT03286842
What this trial is testing

To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.

Who this might be right for
HER2-ve Metastatic Breast CancerGermline BRCA1/2 MutationsSomatic BRCA1/2 Mutations
AstraZeneca 256
Large-scale testing (Phase 3)Looking for participantsNCT02000089
What this trial is testing

The Cancer of the Pancreas Screening-5 CAPS5)Study

Who this might be right for
Pancreas CancerPeutz-Jeghers Syndrome (PJS)Gene Mutation+2 more
Johns Hopkins University 9,000
Testing effectiveness (Phase 2)Active Not RecruitingNCT02286687
What this trial is testing

Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes

Who this might be right for
Advanced Malignant NeoplasmATM Gene MutationBRCA1 Gene Mutation+5 more
M.D. Anderson Cancer Center 150
Large-scale testing (Phase 3)Active Not RecruitingNCT02032823
What this trial is testing

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer

Who this might be right for
Breast Cancer
AstraZeneca 1,837
Testing effectiveness (Phase 2)Ended earlyNCT04171700
What this trial is testing

Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes

Who this might be right for
Solid Tumor
pharmaand GmbH 83
Testing effectiveness (Phase 2)WithdrawnNCT03933761
What this trial is testing

Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy

Who this might be right for
Ovarian CancerCarcinosarcoma
Australia New Zealand Gynaecological Oncology Group
Next Page